Human Drug Metabolism Database

The IUPAC’s Drug Discovery and Development Subcommittee (D3SC) has long been considering the assembly of a human drug metabolism database (hDMdb) that, in particular, might be a useful tool for interdisciplinary scientists engaged in small molecule drug discovery or toxicology.  Ideally, it would be available online at no (or minimal) cost similar to the Protein Data Bank.  Prominent applications would be to have an established compilation of human data from which each user could confidentially:

  • Predict the biological disposition of new (e.g. proprietary) compounds relative to metabolic possibilities and, more importantly, relative to statistically-derived and ranked metabolic probabilities;
  • Assess the value of preclinical in vitro and in vivo models for predicting human drug metabolism, drug-drug interactions, and off-target toxicity when preceded by one or more competing bioactivation versus detoxification events;
  • Develop general and/or proprietary methods to account for 3D chemical structures and derive structure-metabolism/transporter relationships for specific metabophores or structurally-related families of compounds; and,
  • Explore machine learning (AI and ‘facial recognition’ at the molecular level) relative to drug metabolism in both humans and in preclinical in vitro and in vivo models of human drug metabolism.

The accompanying paper describes what we were initially thinking in more technical detail (J. Current Drug Metabolism, 2003, 4, 411-422; PDF).  Current interest in exploiting AI within the context of drug discovery suggests that the concept outlined in this article may be even more relevant today than when it was first being contemplated several years ago (e.g. see Drug Metabolism – Databases and High-Throughput Testing During Drug Design and Development published for the IUPAC by Blackwell Sciences Ltd. 1999; ISBN 0-632-05342-9).

 

For various reasons we made limited progress past the early testing points noted in this initial paper.  Alternatively, we feel that databases and the field of predicting/assessing drug metabolism have, in general, moved forward considerably in several directions over the last twenty years.  Thus, we now envision writing a white paper update (pros and cons) about today’s status of this topic and where it may be heading in the future.  For that we are seeking your assistance in whatever way you may want to help, and specifically toward answering three questions.  Depending upon which you prefer, your input can be cited in: (a) A non-identifying, confidential manner for you and your organization; (b) An acknowledgement of you and/or your organization; or (c) As a specifically cited reference including as much detail as you may want.  Either way, we are not requesting any proprietary information or details for unpublished methods.  The three questions are:

  • Is there still a need for a hDMdb like the one described above or for some other version; and can you please elaborate what resources are available for you to currently use in this regard and indicate any missing features that would add value if they could be incorporated?
  • What other types of resources are available or are you trying to develop internally, for you to address items (i) to (iv) above, especially with regard to the cutting-edge machine learning (AI) arena as it might be applied to the field of small molecule drug metabolism?
  • Given today’s interest in small molecule bio-conjugates such as ADCs, and the deployment of immune-related biomolecules as therapeutics, would it be useful to have: (a) A glossary and/or tutorial pertaining to the biological disposition/metabolism of medium and/or large molecule therapeutics, perhaps something like our recently published document pertaining to small molecule therapeutics (Pure Appl. Chem., 2021, 93, 273-403 and then republished in the ACS series Medicinal Chemistry Reviews, 2021, 56, 463-659); and/or (b) A hDMdb something like the one described above but instead dedicated to (focused upon) metabolism data collected only from medium/large molecule (biomolecule) therapeutics?

Any other comments you may want to contribute toward this topic, beyond the questions noted above, are most certainly, additionally welcome.  They may also become important for adding to the intended white paper.  Please note the level of recognition that you would like to have for whatever additional information you choose to share.

We respectfully request any assistance you can provide for this non-profit undertaking which we hope will be of specific value to the drug metabolism, drug discovery-development, and toxicology fields, as well as to the global pharmaceutical corporate-academic-public enterprise in general.  Please send your response via email attachment to [email protected] by no later than September 30, so that a summary white paper can be issued in early 2025.

 

For more information and comment, contact Task Group Chair Paul Erhardt <[email protected] > | https://iupac.org/project/2011-018-1-700/

 

Featured image: Photo by National Cancer Institute on Unsplash

Comments are closed.